Clinical trial
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase…
NCT00301093 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00301093 |
|---|---|
| Title | Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | GM-K562 cell vaccine, imatinib mesylate |
| Enrollment | 3 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | Sep 10, 2020 |
| First posted | Mar 10, 2006 |
| Last update posted | Oct 28, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: